Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2009 1
2010 1
2011 1
2012 1
2018 1
2020 1
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Innate immunity and cancer therapy.
Maruyama K, Selmani Z, Ishii H, Yamaguchi K. Maruyama K, et al. Among authors: selmani z. Int Immunopharmacol. 2011 Mar;11(3):350-7. doi: 10.1016/j.intimp.2010.09.012. Epub 2010 Oct 16. Int Immunopharmacol. 2011. PMID: 20955832 Review.
FGFR alterations in urothelial carcinoma: Picking the right target.
Hubert P, Selmani Z, Loriot Y, Thiery-Vuillemin A. Hubert P, et al. Among authors: selmani z. Bull Cancer. 2021 Jun;108(6):566-570. doi: 10.1016/j.bulcan.2021.02.014. Epub 2021 May 18. Bull Cancer. 2021. PMID: 34020787 No abstract available.
Enterocolitis in Patients with Cancer Treated with Docetaxel.
Fiteni F, Paillard MJ, Orillard E, Lefebvre L, Nadjafizadeh S, Selmani Z, Benhamida S, Roland A, Baumann A, Vienot A, Houédé N, Pivot X. Fiteni F, et al. Among authors: selmani z. Anticancer Res. 2018 Apr;38(4):2443-2446. doi: 10.21873/anticanres.12497. Anticancer Res. 2018. PMID: 29599375
The "extreme phenotype approach" applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles.
Chevarin M, Alcantara D, Albuisson J, Collonge-Rame MA, Populaire C, Selmani Z, Baurand A, Sawka C, Bertolone G, Callier P, Duffourd Y, Jonveaux P, Bignon YJ, Coupier I, Cornelis F, Cordier C, Mozelle-Nivoix M, Rivière JB, Kuentz P, Thauvin C, Boidot R, Ghiringhelli F, O'Driscoll M, Faivre L, Nambot S. Chevarin M, et al. Among authors: selmani z. Oncotarget. 2023 Feb 7;14:111-125. doi: 10.18632/oncotarget.28358. Oncotarget. 2023. PMID: 36749285 Free PMC article.
Flt3 ligand enhances anti-tumor effects of antibody therapeutics.
Maruyama K, Selmani Z, Ishii H, Tai S, Cheng J, Akimoto S, Watanabe M, Yamaguchi K. Maruyama K, et al. Among authors: selmani z. Int Immunopharmacol. 2012 Mar;12(3):481-6. doi: 10.1016/j.intimp.2011.12.019. Epub 2012 Jan 13. Int Immunopharmacol. 2012. PMID: 22245429
HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study.
Baumann A, Henriques J, Selmani Z, Meurisse A, Lepiller Q, Vernerey D, Valmary-Degano S, Paget-Bailly S, Riethmuller D, Ramanah R, Mougin C, Prétet JL. Baumann A, et al. Among authors: selmani z. Cancers (Basel). 2021 Aug 18;13(16):4149. doi: 10.3390/cancers13164149. Cancers (Basel). 2021. PMID: 34439304 Free PMC article.
12 results